3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,324 shares of the company’s stock, valued at approximately $57,000.

A number of other institutional investors have also recently added to or reduced their stakes in TRDA. KLP Kapitalforvaltning AS bought a new position in Entrada Therapeutics during the 4th quarter worth $36,000. Virtus ETF Advisers LLC bought a new position in Entrada Therapeutics during the 4th quarter worth $68,000. AlphaQuest LLC bought a new position in Entrada Therapeutics during the 4th quarter worth $70,000. Russell Investments Group Ltd. grew its stake in Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company’s stock worth $83,000 after buying an additional 4,811 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Entrada Therapeutics during the 4th quarter worth $137,000. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $8.14 on Tuesday. Entrada Therapeutics, Inc. has a 1 year low of $7.10 and a 1 year high of $21.79. The stock has a fifty day moving average of $8.32 and a two-hundred day moving average of $12.54. The firm has a market capitalization of $308.94 million, a PE ratio of 5.12 and a beta of 0.04.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.36. The company had revenue of $8.75 million during the quarter, compared to analyst estimates of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. Equities research analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Tuesday, May 20th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.